A dual strategy to improve psychotic patients’ compliance using sustained release quetiapine oral disintegrating tablets

1. www.accessdata.fda.gov/drugsatfda.../97/020639ap_Seroquel_apltr.pdf. (Access date November 22, 2015).Search in Google Scholar

2. M. A. Kondo, K. Tajinda and C. Colantuoni, Unique pharmacological actions of atypical neuroleptic quetiapine: possible role in cell cycle/fate control, Transl. Psychiatry 3 (2013) 2-43; DOI: 10.1038/tp.2013.19.10.1038/tp.2013.19Search in Google Scholar

3. J. Locklear, H. Svedsäter. C. Datto and J. Endicott, Effects of once-daily extended release quetiapine fumarate (quetiapine XR) on quality of life and sleep in elderly patients with major depressive disorder, J. Affect. Disord. 149 (2013) 189-195; DOI: 10.1016/j.jad.2013.01.021.10.1016/j.jad.2013.01.021Search in Google Scholar

4. C. Cecchic and P. Canonico, Pharmaceutical formulations and adherence to pharmacological treatment in psychiatry: the example of oral disintegrating tablet of olanzapine, Riv. Psichiatr. 47 (2012) 30-39; DOI: 10.1708/1034.11289.Search in Google Scholar

5. S. K. Srivastava, R. Verma, V. Chandra and S. P. Srivastava. Orally disintegrating tablets: A dosage form that extends the market exclusivity and patient protection, World J. Pharmacy Pharm. Sci. 3 (2014) 526-546.Search in Google Scholar

6. http://reference.medscape.com/drug/seroquel-xr-quetiapine-342984#10 (Access date November 22, 2015).Search in Google Scholar

7. L. V. Allen, N. G. Popovich and H. C. Ansel, Solid Dosage Forms and Solid Modified Release Delivery Systems, in Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems, Lippincott Williams & Wilkins, Philadelphia 2005.Search in Google Scholar

8. G. M. Clarke and J. M. Newton, Short, comparative gastrointestinal transit of pellet systems of varying density, Int. J. Pharm. 114 (1995) 1-11; DOI: 10.1016/0378-5173(94)00200-O.10.1016/0378-5173(94)00200-OSearch in Google Scholar

9. J. Collett and C. Moreton, Modified-Release per Oral Dosage Forms, in Pharmaceuticals: the Science of Dosage Form Design (Ed. M. E. Aulton), Churchill Livingstone, New York 2001, pp. 289-305.Search in Google Scholar

10. M. K. Raval, R. V. Ramani and N. R. Sheth, Formulation and evaluation of sustained release entericcoated pellets of budesonide for intestinal delivery, Int. J. Pharm. Investig. 3 (2013) 203-211. DOI: 10.4103/2230-973X.121294.10.4103/2230-973X.121294Search in Google Scholar

11. M. H. Kumar, K. Samatha, A. Balaji and M. S. Shankar, Recent novel advancements in pellet formulation. A Review, Int. J. Pharm. Sci. Res. 4 (2013) 3803-3822; DOI: 10.13040/IJPSR.0975-8232.4 (10).3803-22.Search in Google Scholar

12. Hoda Maher El Taher, Development of Pelletization Technology for the National Pharmaceutical Industry, Master thesis, Faculty of Pharmacy, Alexandria University.Search in Google Scholar

13. S. El Gamal, V. Naggar and M. Sokar, Colon targeting of mebeverine HCl from pH-dependent tablet formulations, J. Am. Sci. 8 (2012) 632-638.Search in Google Scholar

14. P. Dey and S. Maiti, Orodispersible tablets: A new trend in drug delivery, J. Nat. Sci. Biol. Med. 1 (2010) 2-5; DOI: 10.4103/0976-9668.71663.10.4103/0976-9668.71663Search in Google Scholar

15. S. Sherimeier and P. C. Schmidt, Fast dispersible ibuprofen tablets, Eur. J. Pharm. Sci. 15 (2002) 295-305; DOI: 10.1016/S0928-0987(02)00011-8.10.1016/S0928-0987(02)00011-8Search in Google Scholar

16. C. Reitz and P. Kleinebudde, Solid lipid extrusion of sustained release dosage forms, Eur. J. Pharm. Biopharm. 67 (2007) 440-448; DOI: 10.1016/j.ejpb.2007.03.008.10.1016/j.ejpb.2007.03.008Search in Google Scholar

17. C. M. Adeyeye and J. C. Price, Development and evaluation of sustained-release ibuprofen-wax microspheres. In vitro dissolution studies, Pharm. Res. 11 (1994) 575-579; DOI: 10.1023/A:1018931002991.10.1023/A:1018931002991Search in Google Scholar

18. J. B. Schwartz, A. P. Simonelli and W. I. Higuchi, Drug release from wax matrices. I. Analysis of data with first-order kinetics and with the diffusion-controlled model, J. Pharm. Sci. 57 (1968) 274-277; DOI: 10.1002/jps.2600570206.10.1002/jps.2600570206Search in Google Scholar

19. R. Senjković and I. Jalšenjak, Apparent diffusion coefficient of sodium phenobarbitone in ethylcellulose microcapsules: Effects of capsule size, J. Pharm. Pharmacol. 33 (1981) 279-282; DOI: 10.1111/ j.2042-7158.1981.tb13781.x.Search in Google Scholar

20. J. Hamdani, A. J. Moes and K. Amighi, Physical and thermal characterisation of Precirol® and Compritol® as lipophilic glycerides used for the preparation of controlled-release matrix pellets, Int. J. Pharm. 206 (2003) 47-57; DOI: 10.1016/S0378-5173(03)00229-1.10.1016/S0378-5173(03)00229-1Search in Google Scholar

21. R. Bodmeier, Tableting of coated pellets, Eur. J. Pharm. Biopharm. 43 (1997) 1-8; DOI: 10.1016/S0939-6411(96)00028-8.10.1016/S0939-6411(96)00028-8Search in Google Scholar

22. F. Al Husban, Y. Perrie and A. R. Mohamed, Formulation of multiparticulate systems as lyophilised orally disintegrating tablets, Eur. J. Pharm. Biopharm. 79 (2011) 627-634; DOI: 10.1016/j.ejpb.2011.05.014.10.1016/j.ejpb.2011.05.014Search in Google Scholar

23. F. Lai, E. Pini, F. Corrias, J. Perricci, M. Manconi, A. M. Fadda and C. Sinico, Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freezedrying, Int. J. Pharm. 467 (2014) 27-33; DOI: 10.1016/j.ijpharm.2014.03.047.10.1016/j.ijpharm.2014.03.047Search in Google Scholar

24. http://www.brenntagspecialties.com/en/downloads/Products/Multi_Market_Principals/Ashland/PVP_-_PVP_VA/PVP_Brochure.pdf (access date November 22, 2015).Search in Google Scholar

25. A. K. Nayak and K. Manna, Current developments in orally disintegrating tablet technology, J. Pharm. Educ. Res. 2 (2011) 1-10. Search in Google Scholar

26. C. Michon, B. Cuvelier, B. Launay, A. Parker and G. Takerkart. Study of the compatibility/incompatibility of gelatin/iota-carrageenan/gelatin/water mixtures, Carbohydr. Polym. 28 (1995) 333-336; DOI: 10.1016/0144-8617(95)00096-8.10.1016/0144-8617(95)00096-8Search in Google Scholar

27. R. Chandrasekhar, Z. Hassan, A. M. Smith and F. Al Husban, The role of formulation excipients in the development of lyophilized fast-disintegrating tablets, Eur. J. Pharm. Biopharm. 72 (2009) 119-129; DOI: 10.1016/j.ejpb.2008.11.011.10.1016/j.ejpb.2008.11.01119073253Search in Google Scholar

28. F. Al Husban, Y. Perrie and A. R. Mohammed, Preparation, optimisation and characterization of lyophilized rapid disintegrating tablets based on gelatin and saccharide, Curr. Drug Deliv. 7 (2010) 65-75; DOI: 10.2174/156720110790396427.10.2174/15672011079039642719863486Search in Google Scholar

29. X. Tang and M. J. Pikal, Design of freeze-drying processes for pharmaceuticals: practical advice, Pharmaceut. Res. 21 (2004) 191-200; DOI: 10.1023/B:PHAM.0000016234.73023.75.10.1023/B:PHAM.0000016234.73023.75Search in Google Scholar

30. Guidance for Industry: Orally Disintegrating Tablets, FDA CDER Data Standards Manual, 2008. Search in Google Scholar